Anakinra treatment in patients with gout and type 2 diabetes

Clinical Rheumatology

Volumn 34, Issue 5, 2015, Pages 981-984

  Vitale, Antonio ^a   Cantarini, Luca ^a   Rigante, Donato ^b   Bardelli, Marco ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anakinra; Autoinflammatory disorders; Gout; Interleukin (IL) 1 ; Type 2 diabetes

Indexed keywords

ALLOPURINOL; ANTIDIABETIC AGENT; ANTIGOUT AGENT; ANTIRHEUMATIC AGENT; CARBAMIC ACID DERIVATIVE; COLCHICINE; FEBUXOSTAT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; REPAGLINIDE; URIC ACID;

AGED; BLOOD; CASE REPORT; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERURICEMIA; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BLOOD GLUCOSE; CARBAMATES; COLCHICINE; DIABETES MELLITUS, TYPE 2; FEBUXOSTAT; GOUT; GOUT SUPPRESSANTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERURICEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; METFORMIN; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME; URIC ACID;

EID: 84934962576     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2601-7     Document Type: Review

References (23)

1. Joost PH, van Der Meer JW (2006) The inflammasome: a linebacker of innate defense. N Engl J Med 355:730–732
2. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241
3. Cronstein BN, Sunkureddi P (2013) Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol 19:19–29
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
5. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
6. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al (2004) Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138–8143
7. Ardestani A, Sauter NS, Paroni F, Dharmadhikari G, Cho JH, Lupi R et al (2011) Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization. J Biol Chem 286:17144–17155
8. Carstensen M, Herder C, Kivimäki M, Jokela M, Roden M, Shipley MJ et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59:1222–1227
9. Dinarello CA (2011) Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 269:16–28
10. Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol [Epub ahead of print]
11. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28
12. Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15:R123
13. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839–1848
14. Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64:1462–1470
15. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232:1545–1547
16. van Asseldonk EJ, Stienstra R, Koenen TB, van Tits LJ, Joosten LA, Tack CJ et al (2010) The effect of the interleukin-1 cytokine family members IL-1 F6 and IL-1 F8 on adipocyte differentiation. Obesity (Silver Spring) 18:2234–2236
17. Savic S, Dickie LJ, Wittmann M, McDermott MF (2012) Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 26:505–533
18. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
19. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668
20. Mandrup-Poulsen T, AIDA study group (2013) Interleukin-1 antagonists for diabetes. Expert Opin Investig Drugs 22:965–979
21. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668
22. Richette P, Clerson P, Périssin L, Flipo RM, Bardin T (2013) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis [Epub ahead of print]
23. Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14:e33–e37